Introduction {#Sec1}
============

Osteocalcin is a synthetic osteoblast-specific protein which is involved in the regulation of bone, glucolipid metabolism and in maintaining homeostasis \[[@CR1]--[@CR6]\]. Recent studies have investigated whether osteocalcin is associated with subclinical and clinical atherosclerotic coronary artery disease (CAD), but these studies have yielded inconsistent results. In some cases, studies have found inverse associations between osteocalcin and CAD \[[@CR7]--[@CR12]\]. For example, several studies have shown that subjects with CAD had significantly lower serum osteocalcin level than those without CAD \[[@CR8], [@CR9]\]. Similarly, serum osteocalcin level in subjects with type 2 diabetes mellitus (T2DM) has been found to be inversely correlated with subclinical measures of CAD, such as carotid intima-media thickness (C-IMT) and plaque score, independent of confounding factors \[[@CR10]--[@CR12]\].

In contrast to studies reporting an inverse association, some studies have reported no association or a positive association between serum osteocalcin level and measures of CAD. For example, population-based longitudinal study by Holvik et al. found that there was no association between plasma osteocalcin level and cardiovascular diseases (CVD) in younger-old subjects (65--74 years), but a higher plasma osteocalcin concentration was associated with a reduced risk of CVD in older-old men (≥75 years) while with an increased risk of CVD in older-old women (≥75 years) \[[@CR13]\]. However, other research by Reyes-Garcia et al. observed that subjects with CAD had significantly higher serum osteocalcin level than those without CAD, and that serum osteocalcin level in women was positively correlated with C-IMT \[[@CR14]\].

It is unclear why the studies noted above have reported contradictory findings on the association between serum osteocalcin level and atherosclerosis. The lack of consistency might be due to different study populations, or different degrees of confounding from factors that are associated with serum osteocalcin level, such as metabolic-related variables. In any event, the inconsistent results suggest that additional research into the association between osteocalcin and atherosclerosis is warranted, particularly in metabolically health populations that could help limit confounding from metabolic factors. Accordingly, the present study investigated the association between serum osteocalcin level and subclinical atherosclerosis in metabolically normal subjects without a history of CVD.

Subjects and methods {#Sec2}
====================

Subjects {#Sec3}
--------

Subjects were recruited from the Shanghai Obesity Study (SHOS) between December 2009 and December 2011. The detailed rules for implementation of the SHOS have been described in previous study \[[@CR15]\]. Subjects were included if they met the following criteria for being normal-weight, metabolically healthy individuals: (i) body mass index (BMI) between at least 18.5 and less than 25.0 kg/m^2^ \[[@CR16]\]; (ii) normal glucose tolerance, defined as a fasting plasma glucose (FPG) level less than 6.1 mmol/L and 2-h plasma glucose (2hPG) level less than 7.8 mmol/L \[[@CR17]\]; (iii) normotensive, defined as systolic blood pressure (SBP) less than 130 mmHg and a diastolic blood pressure (DBP) less than 85 mmHg \[[@CR18]\]; (iv) normal lipid status, defined as serum total cholesterol (TC) less than 5.18 mmol/L, serum triglycerides (TG) less than 1.70 mmol/L, serum high-density lipoprotein cholesterol (HDL-C) level of 1.04 mmol/L or higher, and serum low-density lipoprotein cholesterol (LDL-C) less than 3.37 mmol/L \[[@CR19]\]. Subjects were excluded if they had a known history of CVD or carotid plaque, or had any infections, hepatic or renal dysfunction, malignant tumors, or were taking medicine that may influence the level of serum osteocalcin. After applying the inclusion and exclusion criteria noted above, a total of 476 subjects were available for study. The study was approved by the Ethics Committee of Shanghai Jiao Tong University Affiliated Sixth People's Hospital, and was conducted in accordance with the Declaration of Helsinki. Data must be handled so as to not compromise study participants' privacy. All participants provided written informed consent prior to enrollment.

Questionnaire data {#Sec4}
------------------

Each subject answered a standard questionnaire. The questionnaire assessed history of medical conditions, family history of disease, current medications use, and smoking history and other lifestyle factors. Subjects who smoked at least one cigarette per day for over half a year were defined as current smokers \[[@CR15]\].

Anthropometric and laboratory measurements {#Sec5}
------------------------------------------

Height was measured with a stadiometer after the subject had removed his or her shoes and hats. Subjects were required to keep their eye-sight horizontal, with the back of the head, shoulder blades, buttocks, calves, and heels all touching the stadiometer's vertical board, and their height was then recorded to the nearest 0.1 cm. Body weight was measured by a calibrated bathroom scale. Subjects removed their shoes and outer clothing and stood still in the middle of the scale, with feet slightly apart, until the scale's weight reading had stabilized. Subjects' weight was then recorded to the nearest 0.1 kg. BMI was calculated as body weight in kilo-grams divided by height in meters squared. Waist circumference (W) was measured at the horizontal plane between the inferior costal margin and the iliac crest on the mid-axillary line. Blood pressure was measured 3 times with a mercury sphygmomanometer at 3-min intervals, after the subject had been at rest for at lest 10 min. Form these three blood pressure measurements, a mean value was calculated. The techniques for laboratory measurement of blood samples have been described previously \[[@CR15]\]. Serum total osteocalcin level was measured using an electrochemiluminescence immunoassay (Roche Diagnostics GmbH, Mannheim, Germany), and the intra-assay and inter-assay coefficients of variation for osteocalcin were 1.2 to 4.0 % and 1.7 to 6.5 %, respectively \[[@CR15]\].

Ultrasonographic measurement of C-IMT {#Sec6}
-------------------------------------

An experienced radiologist, who was blinded to study results, made ultrasound measurements of C-IMT with a high-resolution B-mode scanner (Voluson 730 Expert; GE Healthcare, Waukesha, WI, USA). A 10-MHz probe was utilized, and C-IMT was measured on both sides of the common carotid artery approximately 1.0 cm proximal to the carotid bulb. The average C-IMT value of the two sides was used for analysis \[[@CR20]\].

Statistical analyses {#Sec7}
--------------------

Variables with normal distributions were described in terms of the mean ± standard deviation, while variables with skewed distribution were described in terms of the median and 25th and 75th percentiles. The independent-sample student's *t*-test (for normally distributed variables) and the Wilcoxon rank-sum test (for skewed variables) were used to assess differences in characteristics between gender groups. Categorical variables were summarized using frequencies and percent, and differences in categorical variables among groups were assessed by the chi-square test. Partial correlations were calculated to analyze C-IMT's association with serum osteocalcin and other clinical variables after adjustment for age. Multivariable linear regression models were run to examine the relationship between C-IMT (dependent variable) and serum osteocalcin level (independent variable) after adjustment for other variables. Statistical Product and Service Solutions software (SPSS for Windows, Version 16.0. Chicago, IL: SPSS Inc.) was used to perform statistical analyses. All statistical tests were two tailed, and p-values less than 0.05 were considered statistically significant.

Results {#Sec8}
=======

Clinical characteristics of study subjects {#Sec9}
------------------------------------------

The 476 subjects enrolled in the present study had an age range of 20 to 75 years (mean 47.9 ± 9.5 years). Subjects were gender-stratified into 155 men, 201 premenopausal women, and 120 postmenopausal women. The years since menopause of postmenopausal women was 5.6 ± 4.6 years. The clinical characteristics of study subjects have been described in Table [1](#Tab1){ref-type="table"}. Men had a significantly higher SBP, DBP level, and a higher frequency of smoking than either premenopausal or postmenopausal women (all *P* \< 0.05). Postmenopausal women had higher levels of W, 2hPG, glycated hemoglobin (HbA1c), TC, TG, LDL-C, and C-reactive protein (CRP) than premenopausal women (all *P* \< 0.05).Table 1Clinical characteristics of study subjectsVariablesMenPremenopausal womenPostmenopausal womenn155201120Age (years)50.1 ± 10.642.0 ± 6.8\*\*55.0 ± 4.4\*\*^,^\*\*\*\*BMI (kg/m^2^)22.0 ± 1.821.5 ± 1.7\*21.7 ± 1.8W (cm)78.0 (74.0--84.0)72.0 (69.5--77.0)\*\*75.0 (71.0--80.0)\*\*^,^\*\*\*\*SBP (mmHg)119.3 (110.0--121.3)110.7 (103.3--120.0)\*\*112.7 (107.7--120.0)\*DBP (mmHg)74.7 (70.0--79.3)72.0 (66.7--79.2)\*71.7 (69.3--78.7)\*FPG (mmol/L)5.1 ± 0.45.1 ± 0.45.1 ± 0.42hPG (mmol/L)5.5 ± 1.15.7 ± 1.06.0 ± 1.0\*\*^,^\*\*\*\*HbA1c (%)5.4 (5.2--5.6)5.4 (5.1--5.6)5.5 (5.3--5.8)\*\*^,^\*\*\*\*FINS (mU/L)5.5 (3.8--7.5)6.4 (4.9--8.8)\*\*6.1 (4.5--7.6)HOMA-IR1.2 (0.8--1.7)1.4 (1.1--2.0)\*\*1.4 (1.0--1.7)TC (mmol/L)4.34 ± 0.484.28 ± 0.544.54 ± 0.43\*\*^,^\*\*\*\*TG (mmol/L)0.88 (0.69--1.17)0.79 (0.61--1.00)\*\*0.87 (0.65--1.16)\*\*\*HDL-C (mmol/L)1.40 (1.25--1.61)1.53 (1.37--1.78)\*\*1.62 (1.45--1.79)\*\*LDL-C (mmol/L)2.65 ± 0.482.50 ± 0.46\*\*2.61 ± 0.44\*\*\*CRP (mg/L)0.5 (0.3--0.8)0.3 (0.2--0.7)\*\*0.5 (0.2--0.8)\*\*\*\*Smoking, n (%)76 (49.0)6 (3.0)\*\*1 (0.8)\*\*CVD family history, n (%)45 (29.0)52 (25.9)47 (39.2)\*\*\*Data were presented as mean ± standard deviation or median (interquartile range)*BMI* body mass index, *W* waist circumference, *SBP* systolic blood pressure, *DBP* diastolic blood pressure, *FPG* fasting plasma glucose, *2hPG* 2-h plasma glucose, *HbA1c* glycated hemoglobin, *FINS* fasting insulin, *HOMA-IR* homoeostasis model assessment-insulin resistance index, *TC* total cholesterol, *TG* triglyceride, *HDL-C* high-density lipoprotein cholesterol, *LDL-C* low-density lipoprotein cholesterol, *CRP* C-reactive protein, *CVD* cardiovascular disease\**P* \< 0.05; \*\**P* \< 0.01 vs. men; \*\*\**P* \< 0.05; \*\*\*\**P* \< 0.01 vs. premenopausal women

Comparison of C-IMT and serum osteocalcin level according to gender categorizes {#Sec10}
-------------------------------------------------------------------------------

The median C-IMT for the total study population was 0.55 mm with an interquartile range of 0.50--0.60 mm. The C-IMT of premenopausal women was significantly lower than that of men \[0.50 (0.50--0.60) mm vs. 0.60 (0.50--0.65) mm, *P* \< 0.001\] and postmenopausal women \[0.50 (0.50--0.60) mm vs. 0.60 (0.55--0.60) mm, *P* \< 0.001\]. However, the difference in C-IMT between men and postmenopausal women was not statistically significant \[0.60 (0.50--0.65) mm vs. 0.60 (0.55--0.60) mm, *P* \> 0.05\].

The overall median (interquartile range) serum osteocalcin level was 17.02 (13.31--21.47) ng/mL, with a level of 18.48 (15.53--21.74) ng/mL in men, 14.36 (11.88--16.79) ng/mL in premenopausal women, and 21.86 (18.15--26.90) ng/mL in postmenopausal women. Serum osteocalcin level in postmenopausal women was significantly higher than in men and premenopausal women (all *P* \< 0.001), while serum osteocalcin level in men was also significantly higher than in premenopausal women (*P* \< 0.001) (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Serum osteocalcin level in subjects with different gender categorizes. Data were shown as median with 25th and 75th percentiles. \**P* \< 0.001 compared with men, ^\#^ *P* \< 0.001 compared with premenopausal women

Association of C-IMT with other anthropometric and biochemical parameters {#Sec11}
-------------------------------------------------------------------------

As shown in Table [2](#Tab2){ref-type="table"}, the correlation between C-IMT and serum osteocalcin level was not significant in men or postmenopausal women after adjustment of age (all *P* \> 0.05). However, in premenopausal women, C-IMT showed a significant, inverse correlation with serum osteocalcin level (*r* = −0.145, *P* = 0.041). Therefore, a stepwise multivariable regression model was run only in premenopausal women to determine if serum osteocalcin level was associated with C-IMT in these subjects, independent of other confounding factors. C-IMT was the dependent variable, and the parameters significantly correlated with C-IMT were set as independent variables, including age, BMI, W, SBP, DBP, FPG, serum fasting insulin (FINS), CRP, smoking status, and CVD family history, and osteocalcin. The model indicated that age, SBP, FPG, FINS and CRP were independently associated with C-IMT (all *P* \< 0.05, Table [3](#Tab3){ref-type="table"}), but that serum osteocalcin level was not independently associated with C-IMT in premenopausal women (*P* \>0.05).Table 2Correlations of C-IMT with various clinical and biochemical parameters after adjustment for ageVariablesMenPremenopausal womenPostmenopausal women*rPrPrP*BMI0.0670.4100.1620.022−0.0270.768W0.1400.0830.1530.030−0.0020.982SBP0.2690.0010.2050.0040.1940.035DBP0.1400.0830.1680.0170.1080.243FPG0.1010.2120.2320.0010.0240.7932hPG−0.0900.264−0.0460.519−0.0200.827HbA1c−0.1370.091−0.0540.4470.0990.286FINS0.2670.0010.262\<0.0010.1030.267HOMA-IR0.2690.0010.283\<0.0010.1030.264TC−0.1410.081−0.0340.630−0.0600.518TG0.1370.0900.0870.220−0.0030.974HDL-C−0.2190.006−0.0460.5180.0350.709LDL-C0.1130.1610.0890.2090.0620.502CRP0.0110.8890.2080.0030.1410.126Osteocalcin0.0340.674−0.1450.041−0.1560.090*C-IMT* carotid intima-media thickness, *BMI* body mass index, *W* waist circumference, *SBP* systolic blood pressure, *DBP* diastolic blood pressure, *FPG* fasting plasma glucose, *2hPG* 2-h plasma glucose, *HbA1c* glycated hemoglobin, *FINS* fasting insulin, *HOMA-IR* homoeostasis model assessment-insulin resistance index, *TC* total cholesterol, *TG* triglyceride, *HDL-C* high-density lipoprotein cholesterol, *LDL-C* low-density lipoprotein cholesterol, *CRP* C-reactive proteinTable 3Association of C-IMT with other anthropometric and biochemical parameters in premenopausal womenIndependent variablesStandardized *βtP*Age0.3004.605\<0.001SBP0.1351.9860.048FPG0.1502.3450.020FINS0.1762.6840.008CRP0.2093.4230.001Independent variables included in premenopausal women were as follows: age, BMI, W, SBP, DBP, FPG, FINS, CRP, smoking status, CVD family history, and osteocalcin. Only the statistical significant parameters correlated with C-IMT were presented in Table [3](#Tab3){ref-type="table"} after stepwise regression analysis*C-IMT* carotid intima-media thickness, *BMI* body mass index, *W* waist circumference, *SBP* systolic blood pressure, *DBP* diastolic blood pressure, *FPG* fasting plasma glucose, *FINS* fasting insulin, *CRP* C-reactive protein, *CVD* cardiovascular disease

Discussion {#Sec12}
==========

Evidences indicate that skeleton works not only as a structural scaffold but also as an endocrine organ. Many bioactive factors secreted from bone, such as osteocalcin and osteoprotegerin, have a regulatory role in energy metabolism \[[@CR21], [@CR22]\]. Recent studies have suggested a potentially important role for osteocalcin in regulating the function of vascular endothelial cells, and the cardiovascular system \[[@CR23], [@CR24]\]. This suggests osteocalcin could be involved in the development of CAD. Several studies have investigated the association between osteocalcin and atherosclerosis, but results have not been consistent. Some studies suggest osteocalcin may actually be protective against early atherosclerosis. For example, a study from Korea demonstrated an independent effect of osteocalcin on vascular endothelial cells, suggesting that osteocalcin could have beneficial effects on atherosclerosis \[[@CR25]\]. Our previous study in high fat diet animals indicate that osteocalcin has an endothelial-protective effect in atherosclerosis through mediating the PI3K/Akt/eNOS signaling pathway, and exogenous osteocalcin can improve the function of human umbilical vein endothelial cells *in vitro* \[[@CR26]\]. Consistent with this result, a study in 1319 postmenopausal women found serum osteocalcin level was independently and inversely correlated with C-IMT \[[@CR27]\].

The arteries plaques and aortic calcifications would emerge in the development and progression of atherosclerosis. Moreover, coronary atherosclerosis is the major adverse cardiac events of atherosclerosis. Likewise, a study from Japan of 50 patients with T2DM found that changes in the serum osteocalcin level were significantly and inversely correlated with plaque score \[[@CR12]\]. Another study of 774 elderly men found that higher osteocalcin level was associated with lower abdominal aortic calcification progression \[[@CR28]\]. Additionally, our group and others have found inverse associations between serum osteocalcin level and coronary atherosclerosis in Chinese men \[[@CR8], [@CR9]\].

However, in contrast to the studies above, some data indicate that osteocalcin shows no association, or even shows a positive association, with atherosclerosis or CVD. Thus, a follow-up study of 1290 Korean men found that the serum osteocalcin level was not associated with the development of CVD, even after adjustment for other risk factors for CVD \[[@CR29]\]. Another 4.1-year follow-up study also reported no association between plasma osteocalcin level and CVD in younger-old subjects (65--74 years) \[[@CR13]\]. A positive correlation between serum osteocalcin level and atherosclerosis was found in a study of 78 patients with T2DM. In particular, the level of osteocalcin in subjects with CAD was higher than in those without CAD, and higher concentrations of osteocalcin were found in women with abnormal IMT, carotid plaques, and aortic calcifications compared to normal women \[[@CR14]\].

It is unclear why the results noted above have been so inconsistent. One possible explanation is that the studies were conducted in different populations and ethnic groups. Another explanation may be that different studies were affected to different degrees by confounding from metabolic factors. Studies have demonstrated there is a close correlations between serum osteocalcin level and glucolipid metabolic disorders, obesity, and metabolic syndrome. Each of these metabolic dysfunctions are related to the progression of atherosclerosis, and therefore, are considered as risk factors for CVD \[[@CR30]\]. Researches indicate that subjects with diabetes or impaired glucose tolerance have significantly lower serum osteocalcin level than the subjects with normal glucose tolerance \[[@CR31], [@CR32]\], and that serum osteocalcin level of subjects with metabolic syndrome are lower than in those without metabolic syndrome \[[@CR33]\]. These findings suggest that the association of osteocalcin with atherosclerosis may be influenced by metabolic variables. Thus, to eliminate potential confounding from metabolic variables, it might be useful to explore the relationship between serum osteocalcin level and atherosclerosis in metabolically healthy persons. In this regard, a study of 638 men with normal glucose tolerance by Ma et al. showed an inverse association between serum osteocalcin level and the prevalence of carotid plaque. However, the study did not account for the influence of other metabolic factors, such as obesity, hypertension and dyslipidemia \[[@CR31]\]. Therefore, to better clarify the relationship of serum osteocalcin level to atherosclerosis without confounding from metabolic variables, the present study excluded subjects with traditional risk factors for CVD (overweight, obesity, hyperglycemia, hypertension, and dyslipidemia), and further eliminated those with history of CVD or carotid plaque. In accordance with the previous findings of gender-related difference in serum osteocalcin concentration \[[@CR32]\], the serum osteocalcin level of postmenopausal women was significantly higher than those of men and premenopausal women in this study. There was no statistically significant correlation between serum osteocalcin level and C-IMT in either men or postmenopausal women. Although an simple correlation between these two factors was found in premenopausal women, a multivariable model failed to demonstrate a significant association between serum osteocalcin level and C-IMT after adjusting for relevant confounding factors. Our previous study involving animal models also found that exogenous osteocalcin was not related to endothelium-dependent relaxation in mice fed with chow diet, which is in agreement with the present study's finding of metabolically healthy human to some extent \[[@CR26]\].

Limitations {#Sec13}
-----------

Because of the cross-sectional nature of this study, we were not able to clarify whether the association between osteocalcin and C-IMT was causal. Thus, additional prospective studies are needed to assess this association. In addition, serum total osteocalcin is composed of uncarboxylated and carboxylated forms. Initial animal and *in vitro* studies indicated that undercarboxylated osteocalcin is the biologically active isoform mediating the metabolic functions. However, several recent clinical studies have demonstrated that not only undercarboxylated but also total osteocalcin were associated with energy metabolism and atherosclerosis as well \[[@CR8], [@CR9], [@CR14]\]. Because lack of an automated assay to examine the uncarboxylated form, our study only measured serum total osteocalcin.

Conclusions {#Sec14}
===========

This study is the first to report that serum osteocalcin level is not independently correlated with C-IMT in a metabolically healthy population.
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